Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein e ϵ 4 Carriers

Journal of Alzheimer's Disease

Volumn 53, Issue 1, 2016, Pages 95-106

  Perkins, Michelle ^a,d   Wolf, Andrew B ^b   Chavira, Bernardo ^a,d   Shonebarger, Daniel ^a   Meckel, J P ^a   Leung, Lana ^a,d   Ballina, Lauren ^a   Ly, Sarah ^c   Saini, Aman ^a   Jones, T Bucky ^a   Vallejo, Johana ^a,d   Jentarra, Garilyn ^a,d   Valla, Jon ^a,d  

^a MIDWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ARIZONA ALZHEIMER S CONSORTIUM   (United States)

Author keywords

Alzheimer's disease; APOE; biomarker; energy metabolism; glucose; ketones; mitochondria; monocarboxylate; neurodegeneration; posterior cingulate

Indexed keywords

3 OXOACID COENZYME A TRANSFERASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; CAVEOLIN; CAVEOLIN 1; CYTOCHROME C OXIDASE; GENOMIC DNA; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE; HEXOKINASE 1; KETONE; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 2; MONOCARBOXYLATE TRANSPORTER 3; MONOCARBOXYLATE TRANSPORTER 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; GLUTAMATE TRANSPORTER; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MONOCARBOXYLATE TRANSPORTER;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; BRAIN MITOCHONDRION; DEFAULT MODE NETWORK; ENERGY METABOLISM; FEMALE; GENETIC RISK; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; YOUNG ADULT; CINGULATE GYRUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ADULT; ALZHEIMER DISEASE; AMINO ACID TRANSPORT SYSTEM X-AG; APOLIPOPROTEIN E4; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION; GYRUS CINGULI; HEXOKINASE; HUMANS; MALE; MITOCHONDRIAL PROTEINS; MONOCARBOXYLIC ACID TRANSPORTERS; RNA, MESSENGER; YOUNG ADULT;

EID: 84976407005     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151205     Document Type: Article

References (83)

1. Fargo K (2014) Alzheimer's Association Report: Alzheimer's disease facts and figures. Alzheimers Dement 10, e47-e92.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, HuangY, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117.
3. Ashford JW,Mortimer JA (2002) Non-familial Alzheimer's disease is mainly due to genetic factors. J Alzheimers Dis 4, 169-177.
4. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, Perls TT, Lipsitz LA, Hyman BT (1996) Clinical and pathological correlates of apolipoprotein E 4 in Alzheimer's disease. Ann Neurol 39, 62-70.
5. Bertram L, Tanzi RE (2008) Thirty years of Alzheimer's disease genetics: The implications of systematic metaanalyses. Nat Rev Neurosci 9, 768-778.
6. EisenbergDTA,KuzawaCW, HayesMG(2010)Worldwide allele frequencies of the human apolipoprotein E gene: Climate, local adaptations, and evolutionary history. Am J Phys Anthropol 143, 100-111.
7. Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority ofADrisk andADpathology. Neurobiol Aging 25, 641-650.
8. Wolf AB, Valla J, Bu G, Kim J, Ladu MJ, Reiman EM, Caselli RJ (2013) Apolipoprotein E as a-amyloidindependent factor in Alzheimer's disease. Alzheimers Res Ther 5, 38.
9. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303.
10. Kanekiyo T, Xu H, Bu G (2014) ApoE and A in Alzheimer's disease: Accidental encounters or partners? Neuron 81, 740-754.
11. Mahley RW, Huang Y (2012) Apolipoprotein E sets the stage: Response to injury triggers neuropathology. Neuron 76, 871-885.
12. Mahley RW,Weisgraber KH, Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 103, 5644-5651.
13. Wolf AB, Caselli RJ, Reiman EM, Valla J (2013) APOE and neuroenergetics: An emerging paradigm in Alzheimer's disease. Neurobiol Aging 34, 1007-1017.
14. Reiman EM, Jagust WJ (2012) Brain imaging in the study of Alzheimer's disease. Neuroimage 61, 505-516.
15. Trachtenberg AJ, Filippini N, Mackay CE (2012) The effects ofAPOE 4 on theBOLDresponse. Neurobiol Aging 33, 323-334.
16. LiuY,Yu J-T,Wang H-F, Han P-R, Tan C-C,Wang C, Meng X-F, Risacher SL, Saykin AJ, Tan L (2015) APOE genotype and neuroimaging markers of Alzheimer's disease: Systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 86, 127-134.
17. Atamna H, Frey WH (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7, 297-310.
18. Swerdlow RH (2014) Bioenergetic medicine. Br J Pharmacol 171, 1854-1869.
19. Reiman EM, Caselli RJ, Yun L, Chen K, Bandy D, Minoshima S, Thibodeau S, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the 4 allele for apolipoprotein E. N Engl J Med 334, 752-758.
20. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders A, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101, 284-289.
21. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders A, Hardy J (2005) Correlations between apolipoprotein E 4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 102, 8299-8302.
22. Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147, 180-195.
23. Tomasi D, Wang G, Volkow N (2013) Energetic cost of brain functional connectivity. Proc Natl Acad Sci U S A 110, 13642-13647.
24. Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, Raichle ME (2010) Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci U S A 107, 17757-17762.
25. Vlassenko AG, Benzinger TLS, Morris JC (2012) PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta 1822, 370-379.
26. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME, Mintun MA (2010) Spatial correlation between brain aerobic glycolysis and amyloid-(A) deposition. Proc Natl Acad Sci U S A 107, 17763-17767.
27. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, MintunMA(2005) Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25, 7709-7717.
28. Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM (2010) Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE 4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis 22, 307-313.
29. Huang Y (2010) Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med 16, 287-294.
30. Kim J, Yoon H, Basak J, Kim J (2014) Apolipoprotein E in synaptic plasticity and Alzheimer's disease: Potential cellular and molecular mechanisms. Mol Cells 37, 767-776.
31. Valla J, Berndt JD, Gonzalez-Lima F (2001) Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: Superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 21, 4923-4930.
32. Valla J, Schneider L, Small A, Gonzalez-Lima F (2007) Quantitative cytochrome oxidase histochemistry: Applications in human Alzheimer's disease and animal models. J Histotechnol 30, 235-247.
33. Attwell D, Laughlin SB (2001) An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21, 1133-1145.
34. Magistretti PJ, Pellerin L (1999) Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 354, 1155-1163.
35. Magistretti PJ, Allaman I (2015) A cellular perspective on brain energy metabolism and functional imaging. Neuron 86, 883-901.
36. Pfrieger FW (2003) Outsourcing in the brain: Do neurons depend on cholesterol delivery by astrocytes? BioEssays 25, 72-78.
37. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9, 811-818.
38. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S (2004) Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 25, 311-314.
39. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC (2009) Study of the ketogenic agentAC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab 6, 31.
40. Minoshima S, Foster NL, Kuhl DE (1994) Posterior cingulate cortex in Alzheimer's disease. Lancet 344, 895.
41. Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, Weeber EJ, Turner RS, Xu B, Rebeck GW, Hoe H-S (2009) ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 29, 15317-15322.
42. Douglas D, Jerskey B, Chen K, Protas H, Thiyyagura P, Roontiva A, Muircheartaigh JO, Dirks H, Waskiewicz N, Lehman K, Siniard AL, Turk MN, Hua X, Madsen SK, Thompson PM, Fleisher AS, Huentelman MJ, Deoni SCL, Reiman EM (2014) Brain differences in infants at differential genetic risk for late-onset Alzheimer disease a cross-sectional imaging study. JAMA Neurol 71, 11-22.
43. Knickmeyer RC, Wang J, Zhu H, Geng X, Woolson S, Hamer RM, Konneker T, Lin W, Styner M, Gilmore JH (2014) Common variants in psychiatric risk genes predict brain structure at birth. Cereb Cortex 24, 1230-1246.
44. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 35, 546-551.
45. Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, Sengillo JD, Hillman S, Kong P, Nelson AR, Sullivan JS, Zhao Z, Meiselman HJ, Wenby RB, Soto J, Abel ED, Makshanoff J, Zuniga E, Vivo De DC, Zlokovic BV (2015) GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 18, 521-530.
46. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516.
47. Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E. JAMA Neurol 70, 440-444.
48. Mooradian AD, Chung HC, Shah GN (1997) GLUT1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging 18, 469-474.
49. Huang Y (2011) Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: Lessons from ApoE mouse models. Biochem Soc Trans 39, 924-932.
50. Alata W, Ye Y, St-Amour I, Vandal M, Calon F (2015) Human apolipoprotein E ϵ4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J Cereb Blood Flow Metab 35, 86-94.
51. Boado RJ (2001) Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brainderived peptides. Neurosci Res 40, 337-342.
52. Ferreira JM, Burnett AL, Rameau GA (2011) Activitydependent regulation of surface glucose transporter-3. J Neurosci 31, 1991-1999.
53. McClory H, Williams D, Sapp E, Gatune LW, Wang P, DiFiglia M, Li X (2014) Glucose transporter 3 is a rab11-dependent trafficking cargo and its transport to the cell surface is reduced in neurons of CAG140 Huntington's disease mice. Acta Neuropathol Commun 2, 179.
54. Braun NA (2006) Intracellular trafficking of recycling apolipoprotein E in Chinese hamster ovary cells. J Lipid Res 47, 1176-1186.
55. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N (2008) Apolipoprotein E knock-out and knock-in mice: Atherosclerosis, metabolic syndrome, and beyond. J Lipid Res 50, S178-S182.
56. Pierre K, Pellerin L (2005) Monocarboxylate transporters in the central nervous system: Distribution, regulation and function. J Neurochem 94, 1-14.
57. Hertz L, Chen Y, Waagepetersen HS (2015) Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism,-amyloid toxicity and astrocyte function. J Neurochem 134, 7-20.
58. McNally MA, Hartman AL (2012) Ketone bodies in epilepsy. J Neurochem 121, 28-35.
59. Zhong N, Weisgraber KH (2009) Understanding the association of apolipoprotein E4 with Alzheimer disease: Clues from its structure. J Biol Chem 284, 6027-6031.
60. Zhong N, Ramaswamy G, Weisgraber KH (2009) Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function. J Biol Chem 284, 27273-27280.
61. Lu W, Huang J, Sun S, Huang S, Gan S, Xu J, Yang M, Xu S, Jiang X (2015) Changes in lactate content and monocarboxylate transporter 2 expression in A 25-35-treated rat model of Alzheimer's disease. Neurol Sci 36, 871-876.
62. Newington JT, Rappon T, Albers S, Wong DY, Rylett RJ, Cumming RC (2012) Overexpression of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase A in nerve cells confers resistance to amyloid and other toxins by decreasing mitochondrial respiration and reactive oxygen species production. J Biol Chem 287, 37245-37258.
63. SwerdlowRH, Burns JM, KhanSM(2010) The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20, 265-279.
64. Parker W, Filley C, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40, 1302-1303.
65. Parker W, Parks JK, Filley C, Kleinschmidt-DeMasters B (1994) Electron transport chain defects in Alzheimer's disease brain. Neurology 44, 1090-1096.
66. Ankarcrona M, Mangialasche F,WinbladB(2010) Rethinking Alzheimer's disease therapy: Are mitochondria the key? J Alzheimers Dis 20(Suppl 2), S579-S590.
67. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PLR, Jones PK, Petersen RB, Perry G, SmithMA(2001) Mitochondrial abnormalities in Alzheimer' s disease. J Neurosci 21, 3017-3023.
68. Wolf AB, Braden BB, Bimonte-Nelson H, Kusne Y, Young N, Engler-Chiurazzi E, Garcia AN, Walker DG, Moses GSD, Tran H, Laferla F, Lue L, Emerson Lombardo N, Valla J (2012) Broad-based nutritional supplementation in 3xTg mice corrects mitochondrial function and indicates sex-specificity in response to Alzheimer's disease intervention. J Alzheimers Dis 32, 217-232.
69. Nicholson RM, Kusne Y, Nowak LA, LaFerla FM, Reiman EM, Valla J (2010) Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res 1347, 179-185.
70. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, Niedzielko TL, Schneider LE, Mastroeni D, Caselli RJ,KukullWA, Morris JC, Hulette C, Schmechel D, Rogers J, Stephan DA (2008) Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A 105, 4441-4446.
71. Nakamura T, Watanabe A, Fujino T, Hosono T, Michikawa M (2009) Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol Neurodegener 4, 35.
72. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM (2010) A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 10, 375-384.
73. DeMichele-Sweet MAA, Klei L, Devlin B, Ferrell RE, Weamer EA, Emanuel JE, Lopez OL, Sweet RA (2011) No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiol Aging 32, 555.e9-11.
74. Cruchaga C, Nowotny P, Kauwe JSK, Ridge PG, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM,Morris JC, Goate AM (2011) Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol 68, 1013-1019.
75. Maruszak A, Pepłońska B, Safranow K, Chodakowska-Zebrowska M, Barcikowska M, Zekanowski C (2012) TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity. J Alzheimers Dis 28, 309-322.
76. Roses AD (2010) An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch Neurol 67, 536-541.
77. Riha PD, Rojas JC, Gonzalez-Lima F (2011) Beneficial network effects of methylene blue in an amnestic model. Neuroimage 54, 2623-2634.
78. Buckner RL, Andrews-Hanna JR, Schacter DL (2008) The brain's default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124, 1-38.
79. Leech R, Sharp DJ (2014) The role of the posterior cingulate cortex in cognition and disease. Brain 137, 12-32.
80. Stranahan AM, Mattson MP (2011) Metabolic reserve as a determinant of cognitive aging. J Alzheimers Dis 28, 1-9.
81. Cohen AD, Price JC,Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA,Wolk D, Dekosky ST, Mathis CA, Klunk WE (2009) Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: An example of brain reserve. J Neurosci 29, 14770-14778.
82. Jagust WJ, Landau SM (2012) Apolipoprotein E, not fibrillar-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 32, 18227-18233.
83. Sekar S, McDonald J, Cuyugan L, Aldrich J, Kurdoglu A, Adkins J, Serrano G, Beach TG, Craig DW, Valla J, Reiman EM, Liang WS (2015) Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol Aging 36, 583-591.